Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs.

Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Glitza Oliva IC, Marchetti D.

Cancer Res. 2018 Jul 19. pii: canres.0644.2018. doi: 10.1158/0008-5472.CAN-18-0644. [Epub ahead of print]

PMID:
30026332
2.

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

Arudra K, Patel R, Tetzlaff MT, Hymes S, Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P, Diab A, Prieto VG, Nelson K, Curry JL.

J Cutan Pathol. 2018 Jul 18. doi: 10.1111/cup.13319. [Epub ahead of print]

PMID:
30021048
3.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank C, Van De Wiel B, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, Mitchell T, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Jun 25. doi: 10.1093/annonc/mdy226. [Epub ahead of print]

PMID:
29945191
4.

Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.

J Cutan Pathol. 2018 Jun 25. doi: 10.1111/cup.13312. [Epub ahead of print]

PMID:
29943453
5.

Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.

Farah M, Nagarajan P, Curry JL, Tang Z, Kim TB, Aung PP, Torres-Cabala CA, Eterovic AK, Wargo JA, Prieto VG, Tetzlaff MT.

Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881. [Epub ahead of print]

PMID:
29897634
6.

Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.

Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE.

Am J Dermatopathol. 2018 Jun 1. doi: 10.1097/DAD.0000000000001150. [Epub ahead of print]

PMID:
29863571
7.

Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall.

Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):545-549. doi: 10.1111/cup.13263. Epub 2018 May 18.

PMID:
29672900
8.

Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

Dolkar T, Trinidad CM, Nelson KC, Amaria RN, Nagarajan P, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):539-544. doi: 10.1111/cup.13262. Epub 2018 May 16.

PMID:
29665030
9.

Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers.

Mauzo SH, Milton DR, Prieto VG, Torres-Cabala CA, Wang WL, Chakravarti N, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Brown RE, Aung PP.

Ann Diagn Pathol. 2018 Jun;34:151-154. doi: 10.1016/j.anndiagpath.2018.03.005. Epub 2018 Mar 15.

PMID:
29660567
10.

Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.

Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.

J Cutan Pathol. 2018 Jul;45(7):504-507. doi: 10.1111/cup.13150. Epub 2018 Apr 23.

PMID:
29633300
11.

Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma.

Al-Rohil RN, Milton DR, Nagarajan P, Curry JL, Feldmeyer L, Torres-Cabala CA, Ivan D, Prieto VG, Tetzlaff MT, Aung PP.

Hum Pathol. 2018 Jul;77:98-107. doi: 10.1016/j.humpath.2018.03.017. Epub 2018 Mar 28.

PMID:
29601841
12.

Update on Merkel Cell Carcinoma.

Tetzlaff MT, Nagarajan P.

Head Neck Pathol. 2018 Mar;12(1):31-43. doi: 10.1007/s12105-018-0898-2. Epub 2018 Mar 20.

PMID:
29556962
13.

The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study.

Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH.

Am J Surg Pathol. 2018 Jun;42(6):726-734. doi: 10.1097/PAS.0000000000001041.

PMID:
29543675
14.

Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.

Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL.

J Immunother Cancer. 2018 Feb 12;6(1):14. doi: 10.1186/s40425-018-0323-0.

15.

Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia.

Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic M.

Clin Exp Dermatol. 2018 Jun;43(4):449-453. doi: 10.1111/ced.13401. Epub 2018 Feb 9.

PMID:
29423961
16.

A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally.

Thakar SD, Sagiv O, Tetzlaff MT, El-Naggar A, Debnam JM, Kandl TJ, Esmaeli B.

Digit J Ophthalmol. 2017 Oct 18;23(4):27-29. doi: 10.5693/djo.03.2017.07.001. eCollection 2017. No abstract available.

17.

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X.

Oncotarget. 2017 Dec 5;8(70):115140-115152. doi: 10.18632/oncotarget.22944. eCollection 2017 Dec 29.

18.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
19.

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA.

Oncoimmunology. 2017 Aug 8;6(12):e1361097. doi: 10.1080/2162402X.2017.1361097. eCollection 2017.

20.

Desmoplastic Melanoma of the Periorbital Region.

Thakar S, Kandl T, Sagiv O, Tripathy D, Tetzlaff MT, Kapur S, Myers J, Hwu WJ, Jaber BMY, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):e48-e52. doi: 10.1097/IOP.0000000000001015.

PMID:
29194286
21.

Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.

Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.

Int J Dermatol. 2017 Nov 20. doi: 10.1111/ijd.13833. [Epub ahead of print]

PMID:
29152725
22.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

24.

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA.

Mult Scler Relat Disord. 2017 Oct;17:12-14. doi: 10.1016/j.msard.2017.06.004. Epub 2017 Jun 22.

PMID:
29055440
25.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

26.

Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy.

Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA.

J Dermatol Sci. 2018 Jan;89(1):88-91. doi: 10.1016/j.jdermsci.2017.08.012. Epub 2017 Sep 1. No abstract available.

PMID:
29030090
27.

TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.

Lefrançois P, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Duvic M, Litvinov IV.

Front Med (Lausanne). 2017 Sep 22;4:153. doi: 10.3389/fmed.2017.00153. eCollection 2017.

28.

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M.

JAMA Dermatol. 2017 Dec 1;153(12):1302-1306. doi: 10.1001/jamadermatol.2017.3593.

PMID:
28980004
29.

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.

Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN.

Nat Commun. 2017 Sep 19;8(1):607. doi: 10.1038/s41467-017-00452-4.

30.

Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.

Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL.

J Cutan Pathol. 2017 Dec;44(12):1080-1086. doi: 10.1111/cup.13044. Epub 2017 Oct 13.

PMID:
28901560
31.

Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.

Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MT.

J Cutan Pathol. 2017 Dec;44(12):1075-1079. doi: 10.1111/cup.13039. Epub 2017 Sep 27.

PMID:
28885734
32.

Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma.

Sagiv O, Thakar SD, Morrell G, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2018 Jan/Feb;34(1):e24-e27. doi: 10.1097/IOP.0000000000000988.

PMID:
28863117
33.

Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease.

Saenz-Ibarra B, Prieto VG, Torres-Cabala CA, Huen A, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Aung PP.

Am J Dermatopathol. 2018 Mar;40(3):e41-e43. doi: 10.1097/DAD.0000000000000986.

PMID:
28857979
34.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

35.

Toward a Molecular-Genetic Classification of Spitzoid Neoplasms.

Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL.

Clin Lab Med. 2017 Sep;37(3):431-448. doi: 10.1016/j.cll.2017.05.003. Review.

PMID:
28802494
36.

Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report.

Lewis DJ, Vin H, Hinojosa T, Tetzlaff MT, Dabaja BS, Duvic M.

J Cutan Med Surg. 2017 Nov/Dec;21(6):568-571. doi: 10.1177/1203475417721425. Epub 2017 Jul 17.

PMID:
28712310
37.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP.

Oncoimmunology. 2017 May 8;6(6):e1321187. doi: 10.1080/2162402X.2017.1321187. eCollection 2017.

38.

Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, Netchiporouk E, Pehr K, Prieto VG, Rahme E, Provost N, Gilbert M, Sasseville D, Duvic M.

Oncoimmunology. 2017 Mar 17;6(5):e1306618. doi: 10.1080/2162402X.2017.1306618. eCollection 2017.

39.

Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.

Agarwal A, Gopinath A, Tetzlaff MT, Prieto VG.

Am J Dermatopathol. 2017 Jul;39(7):504-507. doi: 10.1097/DAD.0000000000000690.

PMID:
28609344
40.

Aberrant expression of FLI-1 in melanoma.

Ramani N, Aung PP, Hwu WJ, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Prieto VG, Torres-Cabala CA.

J Cutan Pathol. 2017 Sep;44(9):790-793. doi: 10.1111/cup.12979. Epub 2017 Jul 10.

PMID:
28605142
41.

Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall.

Valero-Torres A, Prieto VG, Nagarajan P, Torres-Cabala CA, Tetzlaff MT, Curry JL, Ivan D, Aung PP.

Am J Dermatopathol. 2017 Jun;39(6):468-470. doi: 10.1097/DAD.0000000000000713.

PMID:
28525424
42.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

43.

Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.

Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN.

Am J Surg Pathol. 2017 Apr;41(4):431-445. doi: 10.1097/PAS.0000000000000786.

PMID:
28248813
44.

Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy.

Shustef E, Torres-Cabala CA, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Aung PP.

Am J Dermatopathol. 2017 Aug;39(8):e116-e118. doi: 10.1097/DAD.0000000000000859.

PMID:
28248716
45.

Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor.

Konopinski J, Prieto VG, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Fuller GN, Aung PP.

Am J Dermatopathol. 2017 Jul;39(7):545-547. doi: 10.1097/DAD.0000000000000821.

PMID:
28178009
46.

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.

Am J Dermatopathol. 2017 Feb;39(2):121-129. doi: 10.1097/DAD.0000000000000688.

PMID:
28134729
47.

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas.

Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH.

Mod Pathol. 2017 May;30(5):761-772. doi: 10.1038/modpathol.2016.240. Epub 2017 Jan 27.

48.

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Uemura M, Fa'ak F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A.

J Immunother Cancer. 2017 Jan 18;5:7. doi: 10.1186/s40425-017-0208-7. eCollection 2017.

49.

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A.

Cancer Immunol Res. 2017 Feb;5(2):100-105. doi: 10.1158/2326-6066.CIR-16-0223. Epub 2017 Jan 6.

50.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2.

Supplemental Content

Loading ...
Support Center